FUTRUE GmbH has proposed a squeeze-out of minority shareholders in PharmaSGP Holding SE, increasing cash compensation to EUR 30.64 per share following a positive assessment from a neutral expert.

Information on the Target

PharmaSGP Holding SE is a prominent consumer health company specializing in over-the-counter (OTC) pharmaceuticals and healthcare products. The company's focus is primarily on the pharmacy distribution channel, offering a diversified portfolio mainly comprised of natural active ingredients known for their efficacy and minimal side effects. PharmaSGP caters to a variety of chronic medical conditions, including rheumatic pain, nerve pain, and various age-related ailments.

Within Germany, PharmaSGP holds a leading position as the market leader for systemic chemical-free pain relief, featuring its well-known brands RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Their product range also includes treatments for sexual weakness and vertigo symptoms. Since the launch of its initial products in 2012, PharmaSGP has successfully expanded its market presence to several European countries including Austria, Italy, Belgium, Spain, and France. The brand's portfolio was further bolstered in September 2021 with the addition of Baldriparan®, Formigran®, Spalt®, and Kamol®, which enhanced its offerings in the pain and sleep disorder sectors. In 2024, the company's revenue reached €118.8 million with an impressive adjusted EBITDA margin of 31.3%.

Industry Overview in Germany

The pharmaceutical industry in Germany ranks among the largest and most innovative sectors globally. Germany serves as a hub for several multinational pharmaceutical companies, underpinned by a strong